Foghorn Therapeutics Inc.
FHTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001822462
No open-market purchases or sales by Foghorn Therapeutics Inc. insiders were filed in the last 90 days; 102 institutions reported holding it in 13F filings for Q2 2026, worth $219.2M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Foghorn Therapeutics Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 65 | 61 | −4 |
| Shares | 26.1M | 26.2M | +123.7K (+0.5%) |
| Value | $166.5M | $162.8M | −$3.72M (−2.2%) |
New holders (5)
Institutions that held Foghorn Therapeutics Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jacobs Levy Equity Management, Inc | 130,847 | $811.3K | 0.00% |
| Russell Investments Group, Ltd. | 30,017 | $186.1K | 0.00% |
| Susquehanna International Group, LLP | 12,657 | $78.5K | 0.00% |
| Sunbelt Securities, Inc. | 1,600 | $9.62K | 0.00% |
| Slow Capital, Inc. | 655 | $4.06K | 0.00% |
Sold out (9)
Institutions that held Foghorn Therapeutics Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Wade G W & Inc | 107,770 | $688.0K |
| AQR Capital Management LLC | 39,817 | $254.0K |
| Point72 Asset Management, L.P. | 33,000 | $210.5K |
| MetLife Investment Management | 13,632 | $87.0K |
| Metropolitan Life Insurance Co | 1,439 | $9.18K |
| Cubist Systematic Strategies, LLC | 1,400 | $8.93K |
| Point72 Middle East FZE | 37 | $236 |
| Credit Suisse AG | 1 | $6 |
| Simplex Trading, LLC | 66 | $0 |